{$BTAI} ⬇️

🕒 пн, 15 нояб. 2021 г., 12:51:09 MSK BioXcel Therapeutics downgraded to Sell from Buy at Goldman Sachs Goldman Sachs analyst Corinne Jenkins double downgraded BioXcel Therapeutics to Sell from Buy with a price target of $24, down from $55. The analyst says consensus estimates do not reflect the complexity of new drug launches in the hospital setting. While Jenkins sees expansion into agitation due to Alzheimer’s disease as «strategically rational» based on unmet need and BXCL501’s clinical activity in this population, she does not anticipate rapid adoption given the fragmentation of the geriatric care market. The analyst expects downward estimate revisions to result in pressure on the stock over the near-term. #55 #BTAI From channel Pantini Fly А ну всё, значит покупаем😁